Autism patients may benefit from supplementation
By David Liu, PHD
Wednesday Spet 19, 2012 (foodconsumer.org) -- A new study in International Journal of Immunopathology and Pharmacology suggests taking a luteolin formula called NeuroProtek® may help children with autism spectrum disorders.
T.C. Theoharides and colleagues conducted the small trial study and found that among children with autism spectrum disorders using the supplement, 75 percent improved gastrointestinal dysfunction and allergy symptoms.
For the study, the researchers let 37 children aged 4 to 14 years with autism spectrum disorders take the special supplement NeuroProtek® for a period of four months. These children did not receive any benefit from multiple other treatments, which let the researchers to develop a special formula to help these children.
In addition to improving gastrointestinal dysfunction and allergy symptoms, supplementation of NeuroProtek® also improved eye contact and attention in 50 percent of children and social interaction in 25 percent of the children and resumption of speech in 10 percent of children with autism spectrum disorders.
No side or adverse effects were observed in the children using the supplement.
Autism spectrum disorders are on the rise. Although no one knows for sure what causes the disorder, it is observed that oxidative stress, brain inflammation, gastrointestinal dysfunction and allergy symptom commonly show up in children with autism.
The supplement was designed in a way to counter those symptoms seen in children with autism. It included luteolin, a flavone that antioxidant, anti-inflammatory, anti-allergy, and neuroprotective properties. It also included related flavonoids quercetin and rutin together with olive kernel oil.
The researchers suggested that even though this trial was small and without controls, the results were encouraging and potentially autism patients may benefit from taking this supplement.
(Send your news to firstname.lastname@example.org, Foodconsumer.org is part of the Infoplus.com ™ news and information network)
- Biotech and Agribusinesses Spending Heavily to Defeat State GMO Food Labeling Votes
- Sweet News from Mars (Inc)
- HIV/AIDS Update - Approval of Tybost (cobicistat) 150 mg tablets
- Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
- J&J Recalls Tylenol Again